Regeneron Pharmaceuticals Inc. buy Piper Sandler
Summary
This prediction ended on 28.01.26 with a price of €640.00. With a performance of -1.93%, the BUY prediction for Regeneron Pharmaceuticals Inc. by Piper_Sandler closed slightly in the red. Piper_Sandler has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. Dividends of €3.48 are taken into consideration when calculating the performance. Piper_Sandler has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 3.423% | 3.423% | 17.355% |
| iShares Core DAX® | 1.604% | -7.448% | 3.039% |
| iShares Nasdaq 100 | -0.734% | -1.864% | 15.425% |
| iShares Nikkei 225® | 1.296% | -6.795% | 34.306% |
| iShares S&P 500 | -0.394% | -2.336% | 9.907% |
Comments by Piper_Sandler for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Piper_Sandler for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
31.03.26
31.03.27
01.04.26
Stopped prediction by Piper_Sandler for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
01.11.24
01.11.25
02.11.25
Regeneron Pharmaceuticals Inc.
23.08.24
23.08.25
24.08.25

